Drug pipeline 2Q21—accelerated approvals to the fore
نویسندگان
چکیده
منابع مشابه
NEW DRUG APPROVALS Opdivo for Melanoma
NEW DRUG APPROVALS Opdivo for Melanoma Nivolumab injection (Opdivo, BristolMyers Squibb) has received the FDA’s accelerated approval for the treatment of patients with unresectable or metastatic melanoma that has progressed after treatment with specific medications. Nivolumab is a monoclonal antibody that binds to the programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD...
متن کاملNEW DRUG APPROVALS Kybella for Submental Fat
NEW DRUG APPROVALS Kybella for Submental Fat Deoxycholic acid (Kybella, Kythera Biopharmaceuticals Inc.) has received FDA approval to treat moderate-to-severe fat below the chin, called submental fat. The product is not approved or recommended to treat fat outside of the submental area. Kybella is identical to the deoxycholic acid produced in the body, which helps the body absorb fats. A cytoly...
متن کاملNEW DRUG APPROVALS Farydak for Multiple Myeloma
NEW DRUG APPROVALS Farydak for Multiple Myeloma The FDA has approved panobinostat (Farydak, Novartis) to treat multiple myeloma (MM), which kills more than 10,000 mostly older Americans a year. Panobinostat inhibits the activity of histone deacetylases, which may slow the overdevelopment of plasma cells or cause these cells to die. Panobinostat is intended for patients who have received at leas...
متن کاملContribution of NIH funding to new drug approvals 2010–2016
This work examines the contribution of NIH funding to published research associated with 210 new molecular entities (NMEs) approved by the Food and Drug Administration from 2010-2016. We identified >2 million publications in PubMed related to the 210 NMEs (n = 131,092) or their 151 known biological targets (n = 1,966,281). Of these, >600,000 (29%) were associated with NIH-funded projects in ReP...
متن کاملNEW DRUG APPROVALS Dalvance for Skin Infections
NEW DRUG APPROVALS Dalvance for Skin Infections The FDA has approved dalbavancin (Dalvance, Durata Therapeutics) to treat adults’ acute bacterial skin and skinstructure infections (ABSSSIs) caused by certain susceptible bacteria, such as Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains) and Streptococcus pyogenes. Administered intravenously, Dalvance is...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 2021
ISSN: ['1546-1696', '1087-0156']
DOI: https://doi.org/10.1038/s41587-021-01013-3